living with neuroendocrine cancer

NCCN Guidelines for NET Patients
news

The National Comprehensive Cancer Network (NCCN) has recently released a new guideline book for patients  diagnosed with neuroendocrine tumors. With very readable language it discusses what neuroendocrine tumors are, how they are diagnosed, the various types of treatments that are available based on the location your neuroendocrine tumor was found, and treatment decisions. Also included in this guide is a dictionary to easily look up terms related to neuroendocrine tumors,

Dr. Thor & Dr. Tuba present The Future of PRRT & The Team Approach
video

On January 14, 2018, Dr. Thor Halfdanarson and Dr. A. Tuba Kendi from Mayo Clinic Rochester presented to Northwoods NETS. Dr. Tuba, a radiologist from Mayo, has been fronting the Gallium-68 PET/MRI scan center that has been helping detect and diagnose neuroendocrine tumor patients. She is now at the forefront the PRRT (peptide receptor radionuclide therapy) at the Rochester clinic. Dr. Thor presented his vision for the newly designated Neuroendocrine

Meditations for NET Cancer | Mindful Zebra
mindful zebra

If there is one simple thing neuroendocrine cancer patients can do to bring more clarity and calmness to our daily lives is meditation. Even five minutes a day provides a number of health benefits including decreased depression, mood regulation, increased focus, pain alleviation, blood pressure reduction, decreased cellular inflammation, and increased compassion. That’s just to name a few! If you want to read about more of the benefits of meditation,

Results of the largest NET Patient Quality of Life Survey
news

Results from first global survey of neuroendocrine tumor (NET) patients reveal profound impact of this rare cancer on quality of life The International Neuroendocrine Cancer Alliance (INCA) and Novartis announced the quality-of-life results from the first global survey of patients with neuroendocrine tumors (NETs), a rare type of cancer. Nearly 2,000 patients from 12 countries completed the survey, which was a collaborative effort between INCA and Novartis. The results were